Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Targeting BCL-2, BCL-XL, BCL-W and MDM2 in B-Cell Acute Lymphoblastic Leukemia Is Highly Effective Ex Vivo

Helena Hohtari, MD, Shady Awad, MD, Olli Dufva, Swapnil Potdar, MSc, Caroline A Heckman, PhD, Krister Wennerberg, PhD, Satu Mustjoki, MD PhD, Kimmo Porkka, MD PhD

Blood (2018) 132 (Supplement 1): 3975.

https://doi.org/10.1182/blood-2018-99-110610

Published: 2018

Journal Articles

Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice

Qingrong Huang, Shan He, Yuanyuan Tian, Yuting Gu, Pan Chen, Changhong Li, Jiefang Huang, Yongnian Liu, Hongshuang Yu, Min Jin, Shaoyan Hu, Qing Tong, Anqi Ma, Jian Jin, Elizabeth Hexner, Henry Fung, Ran Reshef, Yi Zhang, Yanyun Zhang

Blood (2017) 129 (20): 2737–2748.

https://doi.org/10.1182/blood-2016-08-735886

Published: 2017

Includes: Supplemental data

Journal Articles

Superior Lethal Activity of Novel BET Protein Proteolysis Targeting Chimera (BETP-PROTACs) Versus Betp Bromodomain Inhibitor (BETi) Against Post-Myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells

Dyana T Saenz, PhD, Warren Fiskus, PhD, Kanak Raina, PhD, Taghi Manshouri, PhD, Kevin Coleman, PhD, Jim Winkler, PhD, Yimin Qian, PhD, Andrew Crew, PhD, Angela Shen, MD, Christopher P Mill, PhD, Baohua Sun, MD PhD, Srdan Verstovsek, MD PhD, Craig Crews, PhD, Kapil N. Bhalla, MD

Blood (2016) 128 (22): 747.

https://doi.org/10.1182/blood.V128.22.747.747

Published: 2016

Journal Articles

NPM1-TYK2 Fusion Is an Oncogene and a Novel HSP90-Client Protein

Sudhakiranmayi Kuravi, M.S., Preethi Kunchala, M.S., Siddhartha Ganguly, MD, Sunil Abhyankar, MD, Yogen Saunthararajah, MD, Kojo S. J. Elenitoba-Johnson, MD, Jensen Roy, MD, Joseph McGuirk, DO, Ramesh Balusu, PhD

Blood (2016) 128 (22): 4127.

https://doi.org/10.1182/blood.V128.22.4127.4127

Published: 2016

Journal Articles

HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma

Caron Jacobson, Nadja Kopp, Jacob V. Layer, Robert A. Redd, Sebastian Tschuri, Sarah Haebe, Diederik van Bodegom, Liat Bird, Amanda L. Christie, Alexandra Christodoulou, Amy Saur, Trevor Tivey, Stefanie Zapf, Deepak Bararia, Ursula Zimber-Strobl, Scott J. Rodig, Oliver Weigert, David M. Weinstock

Blood (2016) 128 (21): 2517–2526.

https://doi.org/10.1182/blood-2016-04-711176

Published: 2016

Includes: Supplemental data

Journal Articles

AUY922, a Heat Shock Protein 90 (Hsp90) Inhibitor, Demonstrates Activity in Patients with Myeloproliferative Neoplasms (MPNs)

Gabriella Hobbs, MD, Rivka Litvin, Jihae Ahn, Anna Sophia Mckenney, Michael J. Mauro, MD, Martin S Tallman, MD, Ellin Berman, MD, Mark Lawrence Heaney, MD PhD, Ross L. Levine, MD, Raajit K. Rampal, MD, PhD

Blood (2015) 126 (23): 4075.

https://doi.org/10.1182/blood.V126.23.4075.4075

Published: 2015

Journal Articles

Superior Activity of BET Protein Bromodomain Antagonist-Based Combination with JAK Kinase, PIM Kinase or Heat Shock Protein 90 Inhibitor Against Post-MPN-MF sAML Cells

Dyana T Saenz, Warren Fiskus, PhD, Taghi Manshouri, PhD, Baohua Sun, MD PhD, Stephanie Krieger, Simrit Parmar, MD, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

Blood (2015) 126 (23): 1269.

https://doi.org/10.1182/blood.V126.23.1269.1269

Published: 2015

Journal Articles

Pharmacological Inhibition of Hsp90 Destabilizes the Histone Methyltransferase Ezh2 in Alloreactive T Cells and Reduces Graft-Versus-Host Disease While Retaining Anti-Leukemic Effects in Mice

Qingrong Huang, Shan He, Yuanyuan Tian, Changhong Li, Yuting Gu, Pan Chen, Jiefang Huang, Yongnian Liu, Min Jin, Qi Cao, Ran Reshef, MD, Yi Zhang, Yanyun Zhang

Blood (2015) 126 (23): 234.

https://doi.org/10.1182/blood.V126.23.234.234

Published: 2015

Journal Articles

Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Emma I Andersson, MSc, Shady Adnan, MD MSc, Leopold Sellner, MD, Dorine Bellanger, Alexandra Schrader, Giuliano Crispatzu, Henan Zhang, MD, Carlos C Mateos, PhD, Edgar Faber, MD PhD, Steffen Koschmieder, MD, Tim H. Brummendorf, MD PhD, Krister Wennerberg, PhD, Wei Ding, MD PhD, Marc-Henri Stern, MD PhD, Marco Herling, MD, Simon Anders, PhD, Wolfgang Huber, PhD, Thorsten Zenz, MD, Satu Mustjoki, MD, PhD

Blood (2015) 126 (23): 315.

https://doi.org/10.1182/blood.V126.23.315.315

Published: 2015

Journal Articles

A Profound Biological Difference of Chronic and Blast Phase Chronic Myeloid Leukemia in Ex Vivo Drug Responses

Paavo Pietarinen, MSc, Tea Pemovska, MSc, Emma I Andersson, MSc, Perttu Koskenvesa, MD, Mika Kontro, MD, Swapnil Potdar, MSc, John Patrick Mpindi, MSc, Olli Kallioniemi, MD PhD, Krister Wennerberg, PhD, Caroline A Heckman, PhD, Satu Mustjoki, MDPhD, Kimmo Porkka, MD PhD

Blood (2014) 124 (21): 3139.

https://doi.org/10.1182/blood.V124.21.3139.3139

Published: 2014

Journal Articles

Newer-Generation HSP90 Inhibitors Can Overcome Ibrutinib Resistance and Suppress Proliferation in Human Mantle Cell Lymphoma in Vitro and in Vivo

Nadja Kopp, MA, Sebastian Tschuri, Sarah Haebe, Diederik van Bodegom, PhD, Liat Bird, Amanda L. Christie, Amy Saur, Alexandra N. Christodoulou, Trevor Tivey, Andrew L Kung, MD PhD, Oliver Weigert, MD, David Weinstock, MD

Blood (2014) 124 (21): 1686.

https://doi.org/10.1182/blood.V124.21.1686.1686

Published: 2014

Journal Articles

Heat Shock Protein 90 Inhibitor NVP-AUY922 Has Potent Anti-Tumor Activity With Adult T-Cell Leukemia-Lymphoma Cells

Hiroaki Taniguchi, MD, Hiroo Hasegawa, MD, PhD, Daisuke Sasaki, PhD, Koji Ando, MD, PhD, Yasushi Sawayama, MD, PhD, Yoshitaka Imaizumi, MD, PhD, Daisuke Imanishi, MD, PhD, Jun Taguchi, MD, PhD, Tomoko Hata, MD, PhD, Kunihiro Tsukasaki, MD, PhD, Katsunori Yanagihara, MD, PhD, Naoki Mori, MD, PhD, Yasushi Miyazaki, MD, PhD

Blood (2013) 122 (21): 1829.

https://doi.org/10.1182/blood.V122.21.1829.1829

Published: 2013

Journal Articles

High-Throughput Drug Sensitivity and Resistance Testing (DSRT) Platform Reveals Novel Candidate Drugs For Advanced Phase BCR-ABL1 -Positive Leukemia

Paavo Pietarinen, MSc, Muntasir Mamun Majumder, MSc, Disha Malani, MSc, Astrid Murumägi, PhD, Tea Pemovska, MSc, Perttu Koskenvesa, MD, Olli Kallioniemi, MD, PhD, Krister Wennerberg, PhD, Caroline A. Heckman, PhD, Satu Mustjoki, MD, PhD, Kimmo Porkka, MD, PhD

Blood (2013) 122 (21): 2719.

https://doi.org/10.1182/blood.V122.21.2719.2719

Published: 2013

Journal Articles

HSP90 Inhibition Has Potent Activity Against T-Cell Acute Lymphoblastic Leukemia (T-ALL) Through Degradation Of TYK2 Kinase

Koshi Akahane, Takaomi Sanda, PhD, Marc R. Mansour, MD PhD FRCPath, Julia Etchin, PhD, Ng Cherry, David M. Weinstock, MD, Anthony Letai, MD, PhD, Daniel J. DeAngelo, MD, Ph.D, A. Thomas Look, MD

Blood (2013) 122 (21): 2528.

https://doi.org/10.1182/blood.V122.21.2528.2528

Published: 2013

Journal Articles

Combined Therapy With BRD4 Antagonist and FLT3 Inhibitor Exerts Synergistic Activity Against Cultured and Primary AML Blast Progenitors Expressing FLT-ITD

Melissa Rodriguez, M.D., Ph.D, Warren Fiskus, Ph.D, Sunil Sharma, MD, Jun Qi, PhD, John A Valenta, M.S., Leasha J Schaub, M.S., Bhavin Shah, Santhana Devaraj, Ph.D, Swaminathan Padmanabhan Iyer, MD, James E Bradner, MD, Kapil N. Bhalla, MD

Blood (2013) 122 (21): 3821.

https://doi.org/10.1182/blood.V122.21.3821.3821

Published: 2013

Journal Articles

Pivotal Role Of Heat Shock Proteins In Monocyte and Endothelial Cell Pathology In Sickle Cell Disease

Nagavedi S. Umapathy, Ph.D, Kavita Natrajan, MBBS, Abdullah Kutlar, MD, Steffen E. Meiler, MD, Julia E. Brittain, PhD

Blood (2013) 122 (21): 969.

https://doi.org/10.1182/blood.V122.21.969.969

Published: 2013

Journal Articles

Intravenous Immunoglobulin G (IVIg) Suppresses HSP70-1 and Has Potential Therapeutic Effects Against Multiple Myeloma and Lymphoma

Richard Julian Jones, Ph.D., Richard E. Davis, M.D., Robert Z. Orlowski, M.D., Ph.D.

Blood (2013) 122 (21): 3845.

https://doi.org/10.1182/blood.V122.21.3845.3845

Published: 2013

Journal Articles

Newer-Generation HSP90 Inhibitors Have Potent Activity Against Human Mantle Cell Lymphoma in Vitro and in Vivo

Oliver Weigert, MD, Diederik van Bodegom, PhD, Liat Bird, Amy Saur, Trevor Tivey, Nadja Kopp, Andrew L. Kung, MD, PhD, David Weinstock, MD

Blood (2012) 120 (21): 1651.

https://doi.org/10.1182/blood.V120.21.1651.1651

Published: 2012

Journal Articles

HSP90 Inhibition Targets JAK2 and Is Highly Effective in CRLF2-Rearranged Acute Lymphoblastic Leukemia

Oliver Weigert, MD, Liat Bird, Nadja Kopp, Andrew A. Lane, MD, PhD, Bjoern Chapuy, MD, PhD, Diederik van Bodegom, Sachie Marubayashi, Akinori Yoda, PhD, Vincent Romanet, MSc, Masato Murakami, MD, PhD, Stephen E. Sallan, MD, Ross L Levine, MD, Andrew L. Kung, MD, PhD, Thomas Radimerski, PhD, David M Weinstock, MD

Blood (2011) 118 (21): 576.

https://doi.org/10.1182/blood.V118.21.576.576

Published: 2011

Journal Articles

Genetic Resistance to JAK2 Enzymatic Inhibitors Is Overcome by HSP90 Inhibition

Oliver Weigert, MD, Andrew A. Lane, MD, PhD, Liat Bird, Nadja Kopp, Angela V Toms, Ph.D., Christoph Gaul, Eric Vangrevelinghe, Alain De Pover, Catherine H. Regnier, PhD, Dirk Erdmann, Francesco Hofmann, PhD, Michael Eck, Andrew L. Kung, MD, PhD, Thomas Radimerski, PhD, David M Weinstock, MD

Blood (2011) 118 (21): 62.

https://doi.org/10.1182/blood.V118.21.62.62

Published: 2011

NARROW

Targeting BCL-2, BCL-XL, BCL-W and MDM2 in B-Cell Acute Lymphoblastic Leukemia Is Highly Effective Ex Vivo

Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice

Superior Lethal Activity of Novel BET Protein Proteolysis Targeting Chimera (BETP-PROTACs) Versus Betp Bromodomain Inhibitor (BETi) Against Post-Myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells

NPM1-TYK2 Fusion Is an Oncogene and a Novel HSP90-Client Protein

HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma

AUY922, a Heat Shock Protein 90 (Hsp90) Inhibitor, Demonstrates Activity in Patients with Myeloproliferative Neoplasms (MPNs)

Superior Activity of BET Protein Bromodomain Antagonist-Based Combination with JAK Kinase, PIM Kinase or Heat Shock Protein 90 Inhibitor Against Post-MPN-MF sAML Cells

Pharmacological Inhibition of Hsp90 Destabilizes the Histone Methyltransferase Ezh2 in Alloreactive T Cells and Reduces Graft-Versus-Host Disease While Retaining Anti-Leukemic Effects in Mice

Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

A Profound Biological Difference of Chronic and Blast Phase Chronic Myeloid Leukemia in Ex Vivo Drug Responses

Newer-Generation HSP90 Inhibitors Can Overcome Ibrutinib Resistance and Suppress Proliferation in Human Mantle Cell Lymphoma in Vitro and in Vivo

Heat Shock Protein 90 Inhibitor NVP-AUY922 Has Potent Anti-Tumor Activity With Adult T-Cell Leukemia-Lymphoma Cells

High-Throughput Drug Sensitivity and Resistance Testing (DSRT) Platform Reveals Novel Candidate Drugs For Advanced Phase BCR-ABL1 -Positive Leukemia

HSP90 Inhibition Has Potent Activity Against T-Cell Acute Lymphoblastic Leukemia (T-ALL) Through Degradation Of TYK2 Kinase

Combined Therapy With BRD4 Antagonist and FLT3 Inhibitor Exerts Synergistic Activity Against Cultured and Primary AML Blast Progenitors Expressing FLT-ITD

Pivotal Role Of Heat Shock Proteins In Monocyte and Endothelial Cell Pathology In Sickle Cell Disease

Intravenous Immunoglobulin G (IVIg) Suppresses HSP70-1 and Has Potential Therapeutic Effects Against Multiple Myeloma and Lymphoma

Newer-Generation HSP90 Inhibitors Have Potent Activity Against Human Mantle Cell Lymphoma in Vitro and in Vivo

HSP90 Inhibition Targets JAK2 and Is Highly Effective in CRLF2-Rearranged Acute Lymphoblastic Leukemia

Genetic Resistance to JAK2 Enzymatic Inhibitors Is Overcome by HSP90 Inhibition

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only